TLK2 and neoplasm: Consistently the latest phosphoproteomic study of TCGA breast tumours by The Clinical Proteomic Tumour Analysis Consortium (CPTAC) independently identified TLK2 as an amplicon-associated highly phosphorylated kinases in luminal breast cancer11, which further support the significance of TLK2 amplification and its preferential association with luminal tumours.